Acute Lymphoblastic Leukemia
Specialty Channel

Featured Article
Treatment with _____ of blinatumomab led to an improvement in EFS when compared with consolidation therapy before allogenic hematopoietic stem cell transplant in young patients with relapsed or…
Blinatumomab leads to an improvement in event-free survival (EFS) when compared to consolidation chemotherapy in young patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL…
True or False: Does inotuzumab ozogamicin yield anti-leukemia activity in young patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)?
True or False: Venetoclax in combination with navitoclax and chemotherapy showed promising efficacy in heavily pretreated pediatric patients with ALL and LBL.
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
True or False: Due to increased toxicity and infection rates in older patients, dose intensification of induction treatment often is no justifiable option. Consequently, new treatment options are…
Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.
Single-agent inotuzumab ozogamicin demonstrated anti-leukemia activity in heavily pre-treated young patients with CD22+ relapsed/refractory ALL.
Venetoclax combined with navitoclax and chemo showed manageable safety and promising efficacy in heavily pretreated patients with ALL and lymphoblastic lymphoma.

News

Blinatumomab leads to an improvement in event-free survival (EFS) when compared to consolidation chemotherapy in young patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL…
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.
Single-agent inotuzumab ozogamicin demonstrated anti-leukemia activity in heavily pre-treated young patients with CD22+ relapsed/refractory ALL.

Interactive Features

Treatment with _____ of blinatumomab led to an improvement in EFS when compared with consolidation therapy before allogenic hematopoietic stem cell transplant in young patients with relapsed or…
True or False: Does inotuzumab ozogamicin yield anti-leukemia activity in young patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)?
True or False: Venetoclax in combination with navitoclax and chemotherapy showed promising efficacy in heavily pretreated pediatric patients with ALL and LBL.
True or False: Due to increased toxicity and infection rates in older patients, dose intensification of induction treatment often is no justifiable option. Consequently, new treatment options are…
Stay in the know.
OncNet Newsletter